

Date : June 26, 2026

Head - Listing
BSE Limited
PJ Towers,
Dalal Street,
Mumbai - 400001

Sub : Compliance Report to be submitted pursuant to Para A(2)(h) of Part I of SEBI Master Circular No. SEBI/HO/CFD/POD-2/P/CIR/2023/93 dated June 20, 2023

Dear Sir / Madam,

It is hereby certified that the draft scheme of amalgamation between Krebs Biochemicals & Industries Limited ("Transferor Company" / "Amalgamating Company") and Ipca Laboratories Limited ("Transferee Company" / "Amalgamated Company") and their respective shareholders and creditors ("Scheme") under Sections 230-232 and other applicable provisions of the Companies Act, 2013, does not, in any way violate, override or limit the provisions of securities laws or requirements of the Stock Exchanges (i.e. National Stock Exchange of India Limited and BSE Limited) and the same is in compliance with the applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations") and the SEBI Master Circular No. SEBI/HO/CFD/POD-2/CIR/2023/93 dated June 20, 2023 ("SEBI Circular"), including the following:

Compliance with the LODR Regulations

Serial	Reference	Particulars	Remarks
1	Regulations 17 to 27 of SEBI LODR Regulations	Corporate Governance requirements	Complied
2	Regulations 11 of SEBI LODR Regulations	Compliance with securities laws	Complied

Compliance with SEBI Circular


Serial	Reference	Particulars	Remarks
(a)	Para (I)(A)(2)	Submission of documents to Stock Exchanges	Complied
(b)	Para (I)(A)(3)	Conditions for schemes of arrangement involving unlisted entities	Not Applicable since the Transferor and Transferee are both listed companies



Ipca Laboratories Ltd.
www.ipca.com

(c)	Para (I)(A)(4)(a)	Submission of Valuation Report	Complied. Report dated June 26, 2026 issued by Mr. Senthil Kumar S (Registration No.: IBBI/RV/06/2022/14652) and Mr. Nataraja Nanjundaiah (Registration No. IBBI/RV/05/2021/13891)), being the Registered Valuers separately appointed by the Transferee Company and the Transferor Company, respectively, recommending the fair share exchange ratio for the proposed amalgamation on the basis of which the Transferee Company will issue shares to the shareholders of the Transferor Company is enclosed as part of this application as Annexure
(d)	Para (I)(A)(5)	Auditors Certificate regarding compliance with Accounting Standards	Complied. Certificates on accounting treatment from the Statutory Auditors' of the Transferor Company and Transferee Company are enclosed as part of this application as Annexure
(e)	Para (I)(A)(10)	Provision of approval of public shareholders through e-voting	Complied. The Transferor Company and Transferee Company shall provide their respective public shareholders with e-voting facility for voting on the Scheme. The Scheme shall be acted upon only if the votes cast by the public shareholders of the Transferor Company and Transferee Company in favour of the Scheme are more than the number of votes cast by the public shareholders of the Transferor Company and Transferee Company against the Scheme.


For Ipca Laboratories Limited



 Harish Kamath
 Corporate Counsel & Company Secretary


For Ipca Laboratories Limited



 Ajit Kumar Jain
 Managing Director & CFO


Ipca Laboratories Ltd.

www.ipca.com


125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

 E: ipca@ipca.com CIN: L24239MH1949PLC007837

Certified that the transactions/ accounting treatment provided in the draft scheme of amalgamation between Krebs Biochemicals & Industries Limited and Ipca Laboratories Limited and their respective shareholders and creditors are in compliance with all the Accounting Standards applicable to a listed entity.

For Ipca Laboratories Limited



Harish Kamath
Corporate Counsel & Company Secretary



For Ipca Laboratories Limited



Ajit Kumar Jain
Managing Director & CFO



Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837